Publications by authors named "Alvan Pope"
Background: Androgen suppression is a central component of prostate cancer management but causes substantial long-term toxicity. Transdermal administration of oestradiol (tE2) circumvents first-pass hepatic metabolism and, therefore, should avoid the cardiovascular toxicity seen with oral oestrogen and the oestrogen-depletion effects seen with luteinising hormone releasing hormone agonists (LHRHa). We present long-term cardiovascular follow-up data from the Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to evaluate the effectiveness of multiparametric magnetic resonance imaging (mpMRI) in identifying clinically significant prostate cancer (csPCa) in real-world clinical settings, particularly among men with elevated prostate-specific antigen (PSA) levels or abnormal examinations.
- The study included 2,642 men from ten sites and found that mpMRI had a high sensitivity (87.3%) and negative predictive value (87.5%) for diagnosing csPCa, although the specificity and positive predictive value were lower (around 50%).
- Using PSA density thresholds improved the diagnostic accuracy, with sensitivity and negative predictive values reaching as high as 96.6% when applying a specific PSA density threshold to low MRI scores. *
Background: The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prostate-specific antigen (PSA) biochemical progression.
Methods: We did a randomised controlled trial enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7-10, positive margins, or preoperative PSA ≥10 ng/mL) for biochemical progression after radical prostatectomy (RADICALS-RT).
Objectives: To compare quality-of-life (QoL) outcomes at 6 months between men with advanced prostate cancer receiving either transdermal oestradiol (tE2) or luteinising hormone-releasing hormone agonists (LHRHa) for androgen-deprivation therapy (ADT).
Patients And Methods: Men with locally advanced or metastatic prostate cancer participating in an ongoing randomised, multicentre UK trial comparing tE2 versus LHRHa for ADT were enrolled into a QoL sub-study. tE2 was delivered via three or four transcutaneous patches containing oestradiol 100 μg/24 h.
A case of discontinuous splenogonadal fusion, diagnosed pre-operatively as a testicular tumor, is described. The condition and potential pre-operative diagnostic methods are explored.
View Article and Find Full Text PDF